Login to Your Account



'Vouching' for Regeneron in PCSK9 market race: Amgen catch-up via coupon buy from Biomarin?

By Randy Osborne
Staff Writer

Thursday, July 31, 2014

In the race with Amgen Inc. to market a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for high cholesterol, Regeneron Pharmaceuticals Inc. played catch-up by buying a priority review voucher (PRV) for $67.5 million from Biomarin Pharmaceutical Inc., splitting the cost with alirocumab partner Sanofi SA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription